CareCloud, Inc. (CCLD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with positive GAAP EPS, increased adjusted EBITDA, and robust free cash flow. The company has a strategic focus on AI, enhancing product competitiveness and operational efficiency, which is positively received by customers. Despite a slight revenue decline due to a non-recurring item, the overall financial health is strong. The Q&A section supports the positive outlook with plans for growth through AI and M&A. Therefore, the stock price is likely to see a positive movement in the next two weeks.
Key Financial Performance
GAAP net income $2.9 million, an improvement of 73% from $1.7 million in the same period last year. The improvement was achieved despite a modest year-over-year revenue decline, driven largely by a one-time non-recurring revenue item in Q2 2024.
GAAP earnings per share (EPS) $0.04 compared to a loss of $0.14 per share in Q2 of 2024. This marks the first time in CareCloud's history that it has delivered positive GAAP EPS.
Year-to-date GAAP net income $4.9 million, more than triple the amount reported in the first half of 2024.
Adjusted EBITDA $12.1 million, a 20% increase year-over-year, reflecting scalability and efficiency of the operating model.
Free cash flow $9 million, up 85% year-over-year, highlighting operational efficiency and financial health.
Revenue for Q2 2025 $27.4 million, down approximately $700,000 year-over-year due to a one-time non-recurring revenue item in Q2 2024.
Direct operating costs Decreased by approximately $760,000 from Q2 2024, reflecting cost management.
Operating expenses (G&A, R&D, sales and marketing) Decreased by approximately $1.4 million year-over-year, indicating disciplined cost control.
Non-GAAP adjusted net income for Q2 2025 $3.3 million, or $0.07 per share, calculated using the end-of-period common shares outstanding.
Adjusted EBITDA for Q2 2025 $6.5 million compared to $6.4 million in the same period last year, showing slight growth.
Revenue for the first 6 months of 2025 $55 million compared to $54.1 million for the same period in 2024, showing a modest increase.
GAAP net income for the first 6 months of 2025 $4.9 million compared to $1.4 million for the same period in 2024, equating to income of $0.02 per share after subtracting preferred stock dividends.
Non-GAAP adjusted net income for the first half of 2025 $5.6 million, or $0.13 per share.
Year-to-date adjusted EBITDA $12.1 million, an increase of $2 million from $10.1 million in the same period last year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-driven products: Launched cirrusAI Notes and cirrusAI Voice to improve documentation accuracy, reduce provider burden, and enhance patient experience. These tools are foundational to a broader platform strategy.
AI Center of Excellence: Fully operational with 100 full-time AI professionals and 100 interns. Focused on embedding AI into workflows to improve efficiency and decision-making.
AI-enabled personal health record (PHR): Developing a PHR with natural language interaction, pre-visit interviews, and proactive care prompts to enhance patient engagement.
Critical Access Hospitals (CAH) market: Received ONC Health IT certification for talkEHR platform tailored for CAH, opening access to a $1.5 billion market across 1,300 rural hospitals.
AI-powered automation: Deployed AI to streamline claims coding, denial management, and accounts receivable workflows, reducing manual work and improving productivity.
Cost efficiency: Reduced operating expenses by $1.4 million year-over-year, reflecting disciplined financial management.
M&A activity: Completed two acquisitions focused on specialty AI-powered RCM, aligning with growth strategy.
AI strategic initiatives: Piloting AI front desk agent and enhanced denial management tools to improve operational efficiency and patient engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company experienced a modest year-over-year revenue decline, attributed to a one-time non-recurring revenue item in Q2 2024. This could indicate challenges in maintaining consistent revenue streams.
Market Competition: The EHR market is described as increasingly crowded, which could pose challenges for CareCloud in differentiating its offerings and maintaining market share.
AI Implementation Risks: While AI is being integrated into operations and products, there is a risk of over-reliance on AI tools, potential errors in AI-driven processes, and challenges in scaling AI solutions effectively.
Economic Uncertainty: The company operates in a dynamic healthcare environment, which could be impacted by broader economic uncertainties affecting client budgets and spending.
Regulatory Compliance: The company’s expansion into new markets, such as critical access hospitals, requires adherence to regulatory standards like ONC Health IT certification, which could pose compliance challenges.
M&A Integration Risks: The company has completed two acquisitions this year and plans to pursue more. There is a risk of integration challenges, cultural mismatches, and failure to realize anticipated synergies.
Dependence on AI Talent: The company has hired 100 AI professionals and onboarded 100 interns. Retaining and effectively utilizing this talent could be a challenge, especially in a competitive market for AI expertise.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: CareCloud reaffirms its full-year 2025 revenue guidance, expecting revenue between $111 million and $114 million.
Adjusted EBITDA Guidance: The company projects adjusted EBITDA in the range of $26 million to $28 million for the full year 2025.
GAAP Earnings Per Share Guidance: CareCloud anticipates GAAP earnings per share between $0.10 and $0.13 for the full year 2025.
AI Initiatives and Product Development: CareCloud is advancing its AI product roadmap, including cirrusAI Notes and cirrusAI Voice, which are gaining traction and enhancing operational efficiency. Future projects include an AI front desk agent, AI-enabled personal health records, and enhanced AI denial management capabilities.
Market Expansion: The company has received ONC Health IT certification for its talkEHR platform tailored for critical access hospitals, opening access to a $1.5 billion addressable market.
M&A Strategy: CareCloud has completed two acquisitions in 2025 and is actively evaluating additional opportunities, focusing on specialty AI-powered RCM.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Preferred Dividend Payments: Since resuming preferred dividend payments, CareCloud has declared 9 consecutive months of distributions, all funded entirely from free cash flow. This consistency reflects operational strength and capital stewardship.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company view the spending and revenue opportunities related to their AI Center of Excellence?
A:The company focuses on three areas: generating incremental revenue through new AI-enabled products, making existing products more competitive with AI features, and optimizing back-office operations to improve efficiency and margins. They believe these efforts will drive revenue, better market positioning, and improved margins.
Q:How is the company approaching sales for new products targeting critical access hospitals and specialized EHRs?
A:The company sees opportunities in providing end-to-end solutions for specialized areas like dermatology and critical access hospitals. They aim to offer better outcomes compared to integrated versions and leverage AI capabilities to address gaps in existing systems. They are targeting a market of approximately 1,300 critical access hospitals in the U.S.
Q:How did medSR remote patient monitoring (RPM) and chronic care management perform?
A:The company reported stable revenue for medSR, with expectations for revenue this year to be roughly equal to last year. RPM contributes about 5% or less to the overall revenue mix, and this trend is expected to continue.
Q:What are the company's incremental opportunities for growth in specialized practices and end-to-end solutions?
A:The company focuses on upselling to the existing client base and exploring new specialty-specific EHRs. They are also targeting smaller healthcare facilities like critical access hospitals and life sciences opportunities. They are tracking well on their four key objectives: AI leadership, revenue stabilization, margin expansion, and acquisitions.
Q:What is the company's strategy and capacity for mergers and acquisitions (M&A)?
A:The company sees an active M&A environment with normalized valuations. They are targeting financially accretive and operationally synergistic acquisitions, leveraging internally generated cash flow and an undrawn credit facility for funding. They aim to deploy AI technology to unlock value in acquired companies.
Q:What is the company's outlook on seasonality and expenses for the second half of the year?
A:The company expects Q3 and Q4 to mirror last year's performance with modest increases. They anticipate free cash flow this year to meet or exceed last year's levels, despite investments in the AI Center of Excellence. Capitalized software expenses focus on AI enhancements to existing platforms.
Q:How are customers responding to the company's AI enhancements?
A:Customer adoption of AI features like cirrusAI Notes has been strong, with over 75% continuing after the trial period. The company sees increasing traction and positive feedback as clients test and adopt AI features, with expectations for even higher adoption rates in the future.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on seasonality impacts for Q3 and Q4, offering only general expectations of mirroring last year's performance with modest increases. Additionally, while discussing M&A funding, they did not provide precise figures or timelines for potential acquisitions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI health
CAH
CareCloud quarter
Co
Non income
PHR
Voice AI
access
assistant
capability
care delivery
certification
cirrusAI Voice
cloud
continuum care
decline item
denial
dividend Non
ecosystem
experience efficiency
generation
health care
improvement
inflection point
intelligence
item CareCloud
machine learning
production
productivity gain
quality
road map
scale
scheduling
today inflection
traction
turnaround time
voice
work turnaround
CCLD Transcript
CareCloud, Inc. (CCLD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial guidance, AI product expansion, and strategic M&A plans, reflecting a positive outlook. The Q&A session supports this with positive feedback on AI products and a clear strategy for margin improvement and customer acquisition. Despite some vagueness in management responses, the overall sentiment is positive, indicating potential stock price appreciation.
CareCloud, Inc. (CCLD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call highlights strong financial performance, with increased revenue guidance and improved cash flows. The strategic focus on AI and the successful integration of acquisitions indicate a promising future. Positive analyst sentiment in the Q&A, especially regarding AI monetization and market opportunities, supports a strong positive outlook. The company's strategic initiatives and robust financial metrics suggest a likely stock price increase exceeding 8%.
CareCloud, Inc. (CCLD) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance with a 9% revenue increase, improved GAAP EPS, and increased adjusted EBITDA. AI initiatives and product development show promise, with successful acquisitions enhancing market reach. The company maintains strong guidance and is strategically positioned for growth. The Q&A section reflects confidence in strategy execution and future profitability. Overall, despite some economic uncertainties and integration risks, the positive financial metrics and strategic initiatives suggest a positive stock price movement in the short term.
CareCloud, Inc. (CCLD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary reveals strong financial performance with positive GAAP EPS, increased adjusted EBITDA, and robust free cash flow. The company has a strategic focus on AI, enhancing product competitiveness and operational efficiency, which is positively received by customers. Despite a slight revenue decline due to a non-recurring item, the overall financial health is strong. The Q&A section supports the positive outlook with plans for growth through AI and M&A. Therefore, the stock price is likely to see a positive movement in the next two weeks.
CCLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
